Neuro-Innovators, LLC

3:00 PM - 3:15 PM (EDT), Monday, June 5, 2023 ・ Session Room 103
Neuro-Innovators, LLC (NIV) is a clinical stage drug company. Its purpose, accelerate brain neuroplasticity (capacity of the brain to remodel, rewire, recover) in patients with brain injury & disease.
NIV engineers novel combinations of existing drugs known to enhance neuroplasticity and impact multiple mechanisms of action in the brain, specific to a disease/ injury. Using FDA approved drugs, NIV is using the FDA’s 505(b)(2) pathway and Fast Track processes, resulting in shorter time to market (3-5 vs. 10+ yrs) & lower cost (~$32M vs. $1+B for New Chemical Entity).
Our first drug, NIV-001, targets patients with chronic motor deficits due to a stroke. Importantly, motor deficits changes are objectively measurable, lowering FDA approval costs and risk. There are 7M US stroke patients costing $50B annually, and creating significant family, and community burdens.
NIV is raising seed funding: $2M; series A & B: $30M; and an acquisition target in 3 yrs, and commercialize NIV-001 in 5 yr
Company Type:
Privately Funded Company
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Placeholder Photo
President & CEO
Neuro-Innovators, LLC